Zerion Pharma

HC Andersen Capital saa maksun yhtiöltä Zerion Pharma DigitalIR/Corporate Visibility -sopimuksesta. Katso vastuuvapauslauseke.

3 sijoittajaa seuraa yhtiötä

Publisher
Zerion Pharma: A disruptive solution for poor drug solubility

Zerion Pharma's CEO Ole Wiborg dived into the potential in the pipeline and the private placement.

Analyytikon kommentti16.03.2023 - Claus Thestrup
Publisher
Presentation of Zerion Pharma by CEO Ole Viborg and CFO Jakob Dynes Hansen

Zerion Pharma is a non-listed Danish company seeking €2-3m in a private placement round. Management will briefly run through the investment proposal and business case. Then management will focus on the regulatory environment governing the Dispersome™ technology, formulation of new drugs, and reformulation of existing drugs. Last but not least CEO Ole Wiborg will give a little flavor on the company’s strategic partnerships.

Analyytikon kommentti21.02.2023 - Claus Thestrup
Publisher
Zerion Pharma – Regulatory environment and strategic partnerships

Meet Zerion Pharma’s management and regulatory team – CEO Ole Wiborg, CFO Jakob Dynnes Hansen, and Mónica González VP Regulatory Affairs. Management will briefly run through the investment proposal and business case. Then management will focus on the regulatory environment governing the Dispersome™ technology, formulation of new drugs, and reformulation of existing drugs. Last but not least CEO Ole Wiborg will give a little flavor on the company’s strategic partnerships.

Video20.02.2023
Publisher
Zerion Pharma - Introduction to the company

Listen to Zerion Pharma’s management team – CEO Ole Wiborg and CFO Jakob Dynnes Hansen introducing the company in relation to a private placement of 2-3 mio. EUR. Zerion Pharma is a non-listed Danish company.

Analyytikon kommentti02.02.2023 - Claus Thestrup